E. Colston

发表

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

I. Lowy, A. Korman, D. Grasela, 2018, PloS one.

Integration of the BALB/c ecotropic provirus into the colony-stimulating factor-1 growth factor locus in a myc retrovirus-induced murine monocyte tumor

M. Cole, W. Baumbach, E. Colston, 1988, Journal of virology.

The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.

R. Bertz, H. Myler, M. Hesney, 2015, British journal of clinical pharmacology.

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Qi Gao, Min Gao, Steven Sheriff, 2017, Journal of medicinal chemistry.

The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor

R. Bertz, T. Marbury, T. Eley, 2015, Antiviral therapy.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.

B. Strober, K. Papp, P. Foley, 2022, Journal of the American Academy of Dermatology.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

B. Strober, M. Gooderham, K. Papp, 2022, Journal of the American Academy of Dermatology.

POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

B. Strober, M. Gooderham, K. Papp, 2021 .

POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

A. Blauvelt, A. Menter, H. Sofen, 2022, Annals of the Rheumatic Diseases.

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

B. Strober, M. Gooderham, A. Blauvelt, 2022, SKIN The Journal of Cutaneous Medicine.

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

C. Coopersmith, R. Hotchkiss, G. Martin, 2019, Intensive Care Medicine.

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

C. Coopersmith, R. Hotchkiss, G. Martin, 2019, Critical care medicine.